Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Withdrawing Ixekizumab in Patients With Psoriatic Arthritis Who Achieved Minimal Disease Activity: Results From a Randomized, Double-Blind Withdrawal Study.
Coates LC, Pillai SG, Tahir H, Valter I, Chandran V, Kameda H, Okada M, Kerr L, Alves D, Park SY, Adams DH, Gallo G, Hufford MM, Hojnik M, Mease PJ, Kavanaugh A; SPIRIT-P3 Study Group. Coates LC, et al. Among authors: hufford mm. Arthritis Rheumatol. 2021 Sep;73(9):1663-1672. doi: 10.1002/art.41716. Epub 2021 Aug 6. Arthritis Rheumatol. 2021. PMID: 33682378 Free PMC article.
The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies.
Kavanaugh A, Gottlieb A, Morita A, Merola JF, Lin CY, Birt J, Shuler CL, Hufford MM, Thaçi D. Kavanaugh A, et al. Among authors: hufford mm. Ann Rheum Dis. 2019 Sep;78(9):1215-1219. doi: 10.1136/annrheumdis-2018-215003. Epub 2019 May 21. Ann Rheum Dis. 2019. PMID: 31113794 Free PMC article. Clinical Trial.
Bamlanivimab and Etesevimab Improve Symptoms and Associated Outcomes in Ambulatory Patients at Increased Risk for Severe Coronavirus Disease 2019: Results From the Placebo-Controlled Double-Blind Phase 3 BLAZE-1 Trial.
Chen P, Behre G, Hebert C, Kumar P, Farmer Macpherson L, Graham-Clarke PL, De La Torre I, Nichols RM, Hufford MM, Patel DR, Naegeli AN. Chen P, et al. Among authors: hufford mm. Open Forum Infect Dis. 2022 Apr 7;9(5):ofac172. doi: 10.1093/ofid/ofac172. eCollection 2022 May. Open Forum Infect Dis. 2022. PMID: 35493124 Free PMC article.
Neutralizing monoclonal antibodies for treatment of COVID-19.
Taylor PC, Adams AC, Hufford MM, de la Torre I, Winthrop K, Gottlieb RL. Taylor PC, et al. Among authors: hufford mm. Nat Rev Immunol. 2021 Jun;21(6):382-393. doi: 10.1038/s41577-021-00542-x. Epub 2021 Apr 19. Nat Rev Immunol. 2021. PMID: 33875867 Free PMC article. Review.
A gut reaction to IL-9.
Hufford MM, Kaplan MH. Hufford MM, et al. Nat Immunol. 2014 Jul;15(7):599-600. doi: 10.1038/ni.2916. Nat Immunol. 2014. PMID: 24940947 Free PMC article.
The development and in vivo function of T helper 9 cells.
Kaplan MH, Hufford MM, Olson MR. Kaplan MH, et al. Among authors: hufford mm. Nat Rev Immunol. 2015 May;15(5):295-307. doi: 10.1038/nri3824. Epub 2015 Apr 7. Nat Rev Immunol. 2015. PMID: 25848755 Free PMC article. Review.
The effector T cell response to influenza infection.
Hufford MM, Kim TS, Sun J, Braciale TJ. Hufford MM, et al. Curr Top Microbiol Immunol. 2015;386:423-55. doi: 10.1007/82_2014_397. Curr Top Microbiol Immunol. 2015. PMID: 25033753 Free PMC article. Review.
24 results